PRECIGEN, INC. Operating Lease Right-of-Use Assets
PRECIGEN, INC. (PGEN) had Operating Lease Right-of-Use Assets of $4.13 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-04
- 2026-06-30: Operating Lease, Right-of-Use Asset $4.13M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $4.37M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $4.68M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $4.86M.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $4.13M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $4.37M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $4.68M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $4.86M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $4.81M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $5.07M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $5.06M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $5.31M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $5.55M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $6.66M 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $7.10M 10-K · filed 2025-03-19 | |
| 2023-09-30 | $7.20M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $7.62M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $7.62M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $8.09M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $8.83M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $8.94M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $10.96M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $9.99M 10-K · filed 2023-03-06 | $10.90M 10-K · filed 2022-03-01 |
| 2021-09-30 | $11.77M 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $12.33M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $8.64M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $9.35M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $19.30M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $20.68M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $24.04M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $11.80M 10-K · filed 2021-03-01 | $25.23M 10-K · filed 2020-03-02 |
| 2019-09-30 | $43.21M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $41.56M 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $43.10M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $0.00 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |